Excelon IP

Directions Website Contact the business

Excelon IP We help you protect your innovation and creativity theough Intellectual property rights like Patent, Trademark, Design Patent and Copyrights.

Know more at https://youtube.com/

Heading to Hamburg for the 2026 AIPPI World Congress. Our Founder, Sanjaykumar Patel , will be there from 7–10 October 2...
09/09/2026

Heading to Hamburg for the 2026 AIPPI World Congress.

Our Founder, Sanjaykumar Patel , will be there from 7–10 October 2026.

Global perspectives. Meaningful connections. Stronger IP strategies.

📩 Meeting requests: [email protected]

01/09/2026

Sirf 3 letters add kiye… phir bhi trademark cancel!

DAPLO aur DAPLOGIN — dekhne aur bolne mein kitne different lagte hain aapko?

Dr. Reddy’s ke registered pharma trademark DAPLO ke against Razenta Pharmaceuticals ka mark tha DAPLOGIN.

Argument tha ki DAPLOGIN, API Dapagliflozin se derive hua hai aur “GIN” suffix usse distinguish karta hai.

But Delhi High Court ka view different tha.

Court ne observe kiya ki DAPLOGIN ke andar DAPLO poora ka poora included hai, aur sirf “GIN” add karne se visual aur phonetic similarity khatam nahi hoti.

Aur pharmaceutical trademarks mein confusion ko courts aur bhi strictly examine karte hain — because medicine brands mein confusion ka impact sirf commercial nahi, patient safety tak ja sakta hai.

IP takeaway:
Existing trademark mein kuch letters add kar dena automatically aapke new brand ko safe nahi banata.

Aap batao — DAPLO vs DAPLOGIN, confusingly similar hai ya clearly different?

[ DAPLO vs DAPLOGIN, DAPLO trademark case, DAPLOGIN trademark, Dr Reddy’s trademark case, Razenta Pharmaceuticals, Delhi High Court trademark case, pharmaceutical trademark, deceptive similarity trademark, pharma brand names, Dapagliflozin trademark, trademark cancellation India, pharma IP, trademark law India, medicine trademark dispute, IP case study ]

29/08/2026

Patent aapne pehle file kiya—but product kisi aur ne pehle launch kar diya. Ab kya?

Sabse pehle, patent kisi raw thought ko protect nahi karta. Patent protection ek eligible invention ke liye hoti hai—whether it relates to a product or a process.
Patent application file karne se aapki priority date secure hoti hai, lekin filing ke turant baad aapko complete enforceable rights nahi mil jaate.

India mein application publish hone ke baad certain provisional rights arise ho sakte hain, but infringement proceedings generally patent grant hone ke baad hi initiate ki ja sakti hain.

Simple takeaway:
Filing secures your priority. Grant enables enforcement.

Kya aapko pehle lagta tha ki patent file karte hi competitor ko legally stop kiya ja sakta hai? Comment karke batayein—and save this reel for future reference.

[ Patent filing in India, patent grant, patent infringement, idea protection, invention protection, pending patent application, patent priority date, startup IP strategy, inventor legal rights, competitor copied invention, Indian patent law, product patent, process patent, innovation protection ]

26/08/2026

Product launch ke time FTO check karna enough nahi hai. IP strategy usse bahut pehle start honi chahiye.

Ek strong product strategy mein IP ka role product selection se hi start ho jata hai.

Market size attractive hai—but IP scenario kya hai?
Target country mein relevant patents kaun-se hain?
Product ko kis direction mein develop karna chahiye?
Regulatory strategy par existing patents ka kya impact ho sakta hai?

Isliye product select karne ke baad IP landscape critical hai.

Aur IP check sirf ek baar nahi.

Product Selection → IP Landscape → Development → IP Clearance → Patent Prosecution → FTO → Launch

Agar development ke during aapne apni innovation par patent file kiya hai, toh generated technical data patent examination ke objections defend karne mein bhi critical role play kar sakta hai.

Before any launch -

Final IP clearance + FTO confirmation is essential.

Because IP ko launch ke end-stage legal formality ki tarah nahi, product-development strategy ka part treat karna chahiye.

Save this as a stage-wise IP checklist—and share it with someone working in R&D, regulatory or product development.

[ IP strategy, stage wise IP checklist, patent landscape, IP landscape, Freedom to Operate, FTO clearance, patent clearance, product selection strategy, product development strategy, patent strategy, pharma IP, pharmaceutical patents, biotech IP, regulatory strategy, patent examination, patent prosecution, product launch clearance, patent risk assessment, R&D IP strategy ]

23/08/2026

Ek promising molecule mil gaya… but patent file karne se pehle disclose kar diya toh?

Pharma R&D mein patent strategy product launch ke time start nahi hoti.

It can start right from the discovery stage.

Jaise hi research team ko promising molecule ya invention identify hota hai, patent filing ka timing extremely important ho sakta hai.

Because agar filing se pehle invention conference, research paper ya kisi public platform par disclose ho jaaye toh woh disclosure patentability ko impact kar sakta hai.

Uske baad journey continue hoti hai:

Discovery → Patent Filing → Pre-clinical → Clinical Trials → Regulatory Approval → Market Launch → IP Commercialisation

Aur market launch ke baad strong IP portfolio company ko apne years of R&D investment se commercial value create karne mein help karta hai.

That’s why pharma mein IP sirf protection nahi—poore innovation lifecycle ki strategy hai.

Aapke according pharma companies ko patent team ko kis stage par involve karna chahiye?

Comment below.

[ pharma patent strategy, drug discovery, patent filing, pharmaceutical R&D, intellectual property, public disclosure, patentability, drug development lifecycle, preclinical trials, clinical trials, regulatory approval, pharma innovation, biotech patents, IP strategy, pharmaceutical commercialization, patent protection, life sciences IP ]

Heading to Hamburg for the 2026 AIPPI World Congress. We are pleased to share that Sanjaykumar Patel, Founder & Principa...
21/08/2026

Heading to Hamburg for the 2026 AIPPI World Congress.

We are pleased to share that Sanjaykumar Patel, Founder & Principal IP Attorney, will be attending the 2026 AIPPI World Congress from 7–10 October 2026.

Looking forward to connecting with the global IP community, exchanging insights, and building meaningful professional relationships in Hamburg.

📍 Congress Center Hamburg, Germany
📅 7–10 October 2026

Want to connect or schedule a meeting with Sanjaykumar Patel during the Congress?
📩[email protected]

See you in Hamburg!

20/08/2026

Biosimilars mein India sirf participate nahi kar raha — global game mein apni position build kar raha hai.

Biocon ka trastuzumab example ek important lesson deta hai.

Original biologic ka patent expire hone ke baad opportunity open hoti hai—but sirf biosimilar develop karna enough nahi hai.

Apna manufacturing process develop karna, us process ke around strong IP build karna, aur manufacturing advantage create karna can become a powerful global strategy.

Aur Biocon ke alawa bhi Indian pharma companies biosimilar space mein aggressively grow kar rahi hain.

Big takeaway:
Biosimilars mein advantage sirf lower cost ka nahi.

It's
Process + IP + Manufacturing = Competitive Edge.

Aapko kya lagta hai—can India become a global biosimilar leader? Comment below.

[ India biosimilars, Biocon biosimilars, trastuzumab biosimilar, Herceptin biosimilar, biosimilar industry India, pharmaceutical IP strategy, process patents pharma, biologics manufacturing, Indian biotech industry, affordable biologics, biosimilar development, pharma patent strategy, biotechnology innovation, Indian pharmaceutical companies, IP strategy in pharma ]

18/08/2026

Generic aur biosimilar SAME cheez nahi hain.

Generic drug ko hum reference drug ke close equivalent ke form mein samajh sakte hain — same active ingredient, strength, dosage form aur route ke saath bioequivalence demonstrate karna hota hai.

Lekin Biosimilar = exact copy nahi.

Biologics living systems se manufacture hote hain, isliye manufacturing aur batch-to-batch level par natural variations possible hoti hain.

Isi liye biosimilar ko technically “highly similar” kaha jata hai — reference biologic ke identical nahi, but clinically meaningful difference bhi nahi hona chahiye.

Aur yahi difference pharma IP aur biosimilar strategy ko much more interesting bana deta hai.

Aapko pehle Generic vs Biosimilar ka ye difference pata tha?

Save karo & Pharma/IP field ke kisi person ke saath share karo.

[ generic vs biosimilar, generic drug, biosimilar, biologics, generic medicine, reference biologic, pharma IP, pharmaceutical patents, biosimilar development, biologic drugs, patent strategy, biotechnology, pharmaceutical industry, drug development, intellectual property, biosimilar explained ]

16/08/2026

Ek drug ko protect karne ke liye 130+ patents?

Humira patent thicket iska one of the most famous examples hai.

Sirf ek basic patent nahi—formulation, treatment, dosage, combination, process, device aur product ke different aspects around multiple patents ka portfolio create kiya ja sakta hai.

Humira ke case mein U.S. patent portfolio itna extensive tha ki biosimilar competitors ke liye market entry ka patent landscape extremely complex ho gaya. Court records have referred to 132 additional Humira-related patents held by AbbVie.

Isi dense web of patent rights ko commonly “Patent Thicket” kaha jata hai.

One product. Multiple layers of IP protection.

Aapke according ye strong IP strategy hai ya excessive patenting? Comment your view

[ Humira patent thicket, Humira patents, AbbVie Humira, patent thicket explained, pharmaceutical patent strategy, biotech patents, biologics patents, biosimilar competition, pharma IP strategy, intellectual property strategy, drug patent protection, pharmaceutical patents, biosimilar market entry, patent portfolio, life sciences IP ]

13/08/2026

₹2.80 lakh ki monthly cancer therapy, sirf ₹8,800 mein—kaise?

2012 mein Natco Pharma ne Bayer ke patented cancer drug Nexavar ke liye compulsory licence apply kiya.

Natco ka case teen important points par based tha:

— Public ki requirement adequately meet nahi ho rahi thi
— Medicine reasonably affordable price par available nahi thi
— Patented invention India mein “worked” nahi thi

Indian Patent Office ne compulsory licence grant kar diya.

Lekin iska matlab patent cancel hona nahi tha. Natco ko specific conditions ke saath medicine manufacture aur sell karne ka legal right mila, jabki Bayer ko royalty milti rahi.

Yeh India ka pehla aur ab tak Section 84 ke under eklauta granted compulsory licence hai.

Aapke according, life-saving medicines ke case mein patent protection aur public access ke beech yeh balance sahi hai?

Comment karke batayein—and is landmark IP case ko save kar lijiye.

[ Compulsory licensing in India, Nexavar case explained, Natco vs Bayer, Section 84 Patents Act, pharmaceutical patent law, affordable cancer medicines, sorafenib tosylate, access to medicines India, Indian Patent Office, patent rights and public interest, landmark IP case India, compulsory licence example ]

Address

627, Gala Empire, Drive In Rd, Thaltej
Ahmedabad
380054

Website

Alerts

Be the first to know and let us send you an email when Excelon IP posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Excelon IP:

Shortcuts

Share

Category